Generics

Innovative Products found!

Biosimilars

Medical devices

Nutraceuticals

Filters

Pp-172 manufacturers

Filters

Filters

Filters , active

Country of origin : China
None products found

pp-172

Concentrate for solution for infusion

Dossier type
CTD
Dossier status
Under development
Country of origin
China
GMP approvals
China
Comments
Indication: Non-small cell lung cancer (NSCLC); oesophageal squamous cell carcinoma (ESCC) Clinical stage: Phase 2 — ongoing in NSCLC and ESCC Modality: Biologic (antibody-drug conjugate; anti-PD-L1 mAb conjugated to cytotoxin) Mechanism / Target: PD-L1-targeted ADC — delivers cytotoxic payload to PD-L1-expressing tumour cells and immunosuppressive cells in TME; dual mechanism: direct cytotoxicity + checkpoint relief via PD-L1 blockade Route / form: Intravenous infusion Differentiation: First PD-L1-targeting ADC in clinical development; combines checkpoint inhibition with targeted cytotoxicity; targets high PD-L1 tumour burden in NSCLC and ESCC
Manufacturer #15340

Clinical-stage and commercial biopharmaceutical company specialising in oncology biologics. Combines proprietary monoclonal antibody and ADC technologies for gastrointestinal and lung cancers. Wholly owned pipeline with Phase 3 and Phase 2 assets advancing globally.
 

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Willing to unlock more features?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.